Cytokines IL-1b, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFa in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

Penson, R. T.; Kronish, K.; Duan, Zhenfeng; Feller, A. C.; Stark, Pinhas; Cook, Sarah; Duska, Linda R.; Fuller, Arlan F.; Goodman, Annekathryn; Nikrui, Najmosama; MacNeill, Kimberley; Matulonis, U.; Preffer, Fred; Seiden, Michael V.

doi:10.1016/s0959-8049(99)81362-8

Cited by 17 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarities between wound healing and tumor formation have long been hypothesized (51). Increased concentrations of IL-1␤, IL-6, and IL-8 have been detected in human ovarian cancer cell lines (52) and in ascites and serum samples from patients with ovarian cancer (53)(54)(55)(56), demonstrating that the pathways used in our genetically transformed cell lines are similar to those in naturally derived ovarian cancer. Furthermore, several of the up-regulated genes identified in our genetically transformed cells, including those superoxide dismutase 2, IL-6, tissue factor pathway inhibitor 2, and stanniocalcin 1, have also been identified independently by others (57) using expression array analysis of naturally derived human ovarian cancer tissue, demonstrating that our genetically defined model involves pathways that are dysregulated in naturally derived ovarian cancer.…”

Section: Discussionmentioning

confidence: 76%

A Genetically Defined Model for Human Ovarian Cancer

Liu¹,

Yang²,

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 76%

A Genetically Defined Model for Human Ovarian Cancer

Liu¹,

Yang²,

et al. 2004

View full text Add to dashboard Cite

show abstract

“…5 Recent studies suggest that IL-8 plays important and multi-functional roles in malignant tumor progression. Most types of cancer have been reported to express high levels of IL-8, including breast cancer, 6 colon cancer, 7 melanoma, 8 lung cancer, 9 bladder cancer 10 and pancreatic cancer. 11 In breast cancer, IL-8 is inversely related to the estrogen receptor (ER) status, which is an important parameter in the management of breast cancer.…”

mentioning

confidence: 99%

Interleukin‐8 modulates growth and invasiveness of estrogen receptor‐negative breast cancer cells

Yao

Lin

Chua

et al. 2007

Intl Journal of Cancer

124

106

View full text Add to dashboard Cite

Breast cancer, especially estrogen receptor (ER)‐negative breast cancer, remains hard to treat despite major advances in surgery and adjuvant therapies. The deletion of ER has been consistently associated with tumor progression, recurrence, metastasis and poor prognosis. Among other differences in biological features, ER‐negative breast cancers express high levels of interleukin‐8 (IL‐8), whereas their ER‐positive counterparts do not. IL‐8 is a multi‐functional cytokine with many important biological functions in tumor formation and development. We aimed to study the role(s) of IL‐8 in ER‐negative breast cancer progression by using RNA interference to specifically knockdown IL‐8 expression in ER‐negative breast cancer cell lines MDA‐MB‐231 and MDA‐MB‐468. In vitro, suppression of IL‐8 led to significant reductions in cell invasion (p < 0.001), but had no effects on cell proliferation or cell cycle. In vivo, suppression of IL‐8 significantly reduced the microvessel density (p < 0.05), and markedly reduced neutrophil infiltration into the tumors (p < 0.05). In contrast to in vitro observations, suppression of IL‐8 promoted tumor growth in nude mice (p < 0.05). Our results imply that the complex roles of IL‐8 in the regulation of ER‐negative breast cancer progression may in part be related to its potent chemotactic effects on neutrophils, which in turn mediates many of the biological functions of IL‐8. © 2007 Wiley‐Liss, Inc.

show abstract

“…In contrast, CCL2 expression has been found to be increased in malignant glioma (Kuratsu et al, 1993;Takeshima et al, 1994), primary and metastatic melanoma (Graves et al, 1992) and glioblastomas and astrocytomas (Desbaillets et al, 1994) compared to corresponding normal tissues. CCL2 expression has also been found to be increased in paclitaxel resistant cell lines and in the serum of ovarian cancer patients following paclitaxel treatment (Duan et al, 1999;Penson et al, 2000). However, rather than being associated with paclitaxel resistance, it is postulated that the increased CCL2 expression may simply reflect stress in the host (Penson et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

“…CCL2 expression has also been found to be increased in paclitaxel resistant cell lines and in the serum of ovarian cancer patients following paclitaxel treatment (Duan et al, 1999;Penson et al, 2000). However, rather than being associated with paclitaxel resistance, it is postulated that the increased CCL2 expression may simply reflect stress in the host (Penson et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma

et al. 2005

View full text Add to dashboard Cite

Chemokine (C-C motif) ligand-2 (CCL2) is a chemoattractant and activator of macrophages and is a key determinant of the macrophage infiltrate into tumours. We demonstrate here that CCL2 is expressed in normal human ovarian surface epithelium (HOSE) cells and is silenced in most ovarian cancer cell lines, and silenced or downregulated in the majority of primary ovarian adenocarcinomas. Analysis of the CCL2 locus at 17q11.2 -q12 showed loss of heterozygosity (LOH) in 70% of primary tumours, and this was significantly more common in tumours of advanced stage or grade. However, we did not detect any mutations in the CCL2 coding sequence in 94 primary ovarian adenocarcinomas. These data support the hypothesis that CCL2 may play a role in the pathobiology of ovarian cancers, but additional studies will be required to evaluate this possibility.

show abstract

Cytokines IL-1b, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFa in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

Cited by 17 publications

References 0 publications

A Genetically Defined Model for Human Ovarian Cancer

A Genetically Defined Model for Human Ovarian Cancer

Interleukin‐8 modulates growth and invasiveness of estrogen receptor‐negative breast cancer cells

Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma

Contact Info

Product

Resources

About